Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida

Journal of Clinical Microbiology

Volumn 49, Issue 11, 2011, Pages 3800-3804

  Pfaller, Michael A ^a   Castanheira, Mariana ^a   Diekema, Daniel J ^b   Messer, Shawn A ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CALCULATION; CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA ORTHOPSILOSIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DILUTION; FUNGAL STRAIN; FUNGUS ISOLATION; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; QUALITY CONTROL; WILD TYPE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA ORTHOPSILOSIS;

EID: 80355137208     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05047-11     Document Type: Article

References (21)

1. Arendrup, M. C., G. Kahlmeter, J. L. Rodriguez-Tudela, and J. P. Donnelly. 2009. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob. Agents Chemother. 53:1628-1629.
2. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2008. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd informational supplement. CLSI, Wayne, PA.
4. Diekema, D. J., et al. 2009. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J. Clin. Microbiol. 47:3170-3177.
5. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington DC.
6. Johnson, E. M. 2009. Rare and emerging Candida species. Curr. Fungal Infect. Rep. 3:152-159.
7. Kahlmeter, G., et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148. (Pubitemid 36986868)
8. Linton, C. J., et al. 2007. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom mycology reference laboratory. J. Clin. Microbiol. 45:1152-1158. (Pubitemid 46626478)
9. Lockhart, S. R., S. A. Messer, M. A. Pfaller, and D. J. Diekema. 2008. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46:2659-2664.
10. Lockhart, S. R., S. A. Messer, M. A. Pfaller, and D. J. Diekema. 2009. Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J. Clin. Microbiol. 47:242-244.
11. Messer, S. A., R. N. Jones, G. J. Moet, J. T. Kirby, and M. Castanheira. 2010. Anidulafungin potency compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp: results from the Global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 48:2984-2987.
12. Pfaller, M. A., et al. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmaclodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 70:330-343.
13. Pfaller, M. A., et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
14. Pfaller, M. A., et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J. Clin. Microbiol. 49:630-637.
15. Pfaller, M. A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values (ECVs) for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
16. Pfaller, M. A., M. Castanheira, S. A. Messer, G. J. Moet, and R. N. Jones. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
17. Pfaller, M. A., and D. J. Diekema. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
18. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431. (Pubitemid 39362350)
19. Pfaller, M. A., et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
20. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
21. Turnidge, J., and D. L. Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408. (Pubitemid 47175010)